Navigation Links
Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs
Date:8/5/2011

LAS VEGAS, Aug. 5, 2011 /PRNewswire/ -- Jury selection in the second trial in the largest hepatitis C outbreak in U.S. history has begun in Clark County, Nevada. The Nevada Supreme Court lifted the stay allowing the case to go to trial when it was determined by the court that nurse David Hambrick, a witness for the defense Teva Inc. and Baxter Inc., "does not possess the requisite skill, knowledge or experience to testify as an expert witness regarding the medical cause of hepatitis C transmission at the Endoscopy Clinic of Southern Nevada," and that the defendants must have qualified, competent expert testimony given to a reasonable degree of medical probability for their alternative causation theory. 

(Photo:  http://photos.prnewswire.com/prnh/20110805/LA48404)

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. 50mL infusion vials of Propofol are meant for long tern sedation of patients, not short outpatient procedures like colonoscopies. Arnold was later diagnosed as having contracted hepatitis C. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor. 

In the complaint filed in Clark County District Court by Mainor Eglet Law Firm attorneys Robert Eglet, Robert Adams and Artemus Ham on behalf of plaintiffs Anne Arnold and spouse James Arnold -- the defendants Teva Parenteral Medicines, Inc.; SICOR Inc. and Baxter Healthcare Corporation -- are each responsible in some manner for causing injury and damages to the plaintiffs.  

"There are two primary issues in the Arnold case: the multi-dosing of Propofol between patients from 50mL jumbo infusion vials not intended for short medical procedures like colonoscopies, and the labels on the vials of Propofol provided inadequate warnings about intended use. Teva and Baxter were responsible for providing 50mL infusion vials of Propofol to the Endoscopy centers because profit dictated the decision to do so. Teva and Baxter's attempt to place the blame exclusively on the health care professionals is a complete disregard for the lives of thousands of Nevadans and their families. Drug companies are not allowed to put profit over patient safety," says Robert Eglet.  


'/>"/>
SOURCE Mainor Eglet Law Firm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Sky One Medical Announces Conference Call to Discuss Second Quarter 2011 Results
2. China Nepstar Chain Drugstore to Report Second Quarter 2011 Financial Results on August 23
3. QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer
4. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
6. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
7. Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results
8. Isis Reports Financial Results and Highlights for Second Quarter 2011
9. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
10. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
11. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Research and Markets has announced the addition of the ... their offering. ... This new report revisits the market potential for self-healing materials from ... 2015. Self-healing is an area of smart coatings and materials with ... potential of $2.7 billion ($US) by 2020. However, in any market ...
(Date:1/17/2017)... TEL AVIV, Israel , January 17, 2017 ... , TyrNovo, Ltd.   KIT-302 Development On ... the FDA in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: ... a business update call on Monday, January 23 rd at 8:30am Eastern ...
(Date:1/17/2017)... 2017  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, plans to announce ... 2016 after the market closes on Wednesday, February 1, ... p.m. ET that day to discuss those results. ... 407-8037 or (201) 689-8037.  For 72 hours following the ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... 17, 2017 , ... Metro Development Group has broken ground ... technology into the fabric of an entire community. A highlight of this new ... in a yet-to-be-named, health focused campus. Leading this initiative in partnership with Metro ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased to ... on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more ... addition to our provider network, and the addition will benefit our members in ...
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, ... to communities throughout the region, is launching a charity drive to raise awareness of ... far the deadliest killer in America, and is responsible for 1 in every 4 ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , the only ... real-time, today announced a strategic partnership with TechLab Security, a leading ... partners, TechLab Security has become a strategic partner and a value added reseller ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Many people make New Year’s resolutions or renew ... Mondavi is making it easier for people who want to kick off 2017 with ... and existing patients. , These special offers include: , , ...
Breaking Medicine News(10 mins):